{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T06:57:09Z","timestamp":1781161029973,"version":"3.54.1"},"reference-count":155,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Transthyretin amyloidosis (ATTR) is a multisystemic disorder associated with extracellular accumulation of misfolded transthyretin (TTR) protein forming insoluble amyloid deposits. Depending on the TTR genotype, ATTR is classified as hereditary ATTR (ATTRv) with pathogenic gene variants and wild-type ATTR (ATTRwt) with a normal TTR genotype. Two cardinal clinical manifestations of ATTR are amyloid cardiomyopathy and peripheral neuropathy, but multisystemic deposition of amyloid may also manifest with ocular and leptomeningeal amyloidosis, various orthopedic complications (carpal tunnel syndrome, spinal stenosis), nephropathy, and gastrointestinal and pulmonary amyloidosis. The natural history of untreated ATTR is characterized by progressive worsening and 25% of patients may die within 24 months from the onset. The first treatment for ATTR was liver transplantation which slows the disease progression, but its use was limited by the scarcity of available liver allografts and complex post-transplant morbidities associated with immunosuppression and various metabolic disturbances. Recent introduction of TTR stabilizers and gene silencing has significantly changed the outcomes and reduced ATTR-related morbidities and mortality, and early diagnosis remains important for improved outcomes. In our narrative expert review, we are discussing epidemiological and clinical features of ATTR, its pathophysiology and available treatments as rapidly progressive fatal disease is being transformed into a treatable chronic disease.<\/jats:p>","DOI":"10.3390\/genes17060680","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:50:58Z","timestamp":1781157058000},"page":"680","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transthyretin Amyloidosis\u2014From Peculiar Neuropathy to a Treatable Chronic Multisystemic Disease"],"prefix":"10.3390","volume":"17","author":[{"given":"Sasha A.","family":"\u017divkovi\u0107","sequence":"first","affiliation":[{"name":"Department of Neurology, School of Medicine, Yale University, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. David","family":"Avila","sequence":"additional","affiliation":[{"name":"Department of Neurology, Geisinger Medical Center, Danville, PA 17821, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic amyloidosis recognition, prognosis, and therapy: A systematic review","volume":"324","author":"Gertz","year":"2020","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/13506129.2011.574354001","article-title":"Amyloidosis: A brief history","volume":"18","author":"Kyle","year":"2011","journal-title":"Amyloid"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2796.1992.tb00625.x","article-title":"History of amyloidosis","volume":"232","author":"Cohen","year":"1992","journal-title":"J. Intern. Med."},{"key":"ref_4","first-page":"84","article-title":"A case of the progressive hypertrophic polyneuritis of dejerine and sottas, with pathological examination","volume":"52","author":"Stern","year":"1921","journal-title":"Brain"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/brain\/75.3.408","article-title":"A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves","volume":"75","author":"Andrade","year":"1952","journal-title":"Brain"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1515\/CCLM.2002.208","article-title":"Transthyretin from discovery to now","volume":"40","author":"Robbins","year":"2002","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_7","first-page":"261","article-title":"Presence of an abnormal transthyretin (prealbumin) in portuguese patients with familial amyloidotic polyneuropathy","volume":"96","author":"Saraiva","year":"1983","journal-title":"Trans. Assoc. Am. Physicians"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/art.1780300210","article-title":"Hereditary amyloidosis: Description of a new american kindred with late onset cardiomyopathy. Appalachian amyloid","volume":"30","author":"Benson","year":"1987","journal-title":"Arthritis Rheum."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0378-1119(85)90272-0","article-title":"Structure of the chromosomal gene for human serum prealbumin","volume":"37","author":"Hiroyuki","year":"1985","journal-title":"Gene"},{"key":"ref_10","unstructured":"(2026, April 18). Mutations in Hereditary Amyloidosis. Available online: http:\/\/amyloidosismutations.com\/mut-attr.php."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/jnnp.59.1.45","article-title":"Familial amyloid polyneuropathy (ttr ala 60) in north west ireland: A clinical, genetic, and epidemiological study","volume":"59","author":"Reilly","year":"1995","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ajmg.1320600606","article-title":"Genetic epidemiology of familial amyloidotic polyneuropathy (fap)-type i in povoa do varzim and vila do conde (north of portugal)","volume":"60","author":"Sousa","year":"1995","journal-title":"Am. J. Med. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/13506129.2013.860027","article-title":"Frequency of the transthyretin val30met mutation in the northern swedish population","volume":"21","author":"Olsson","year":"2014","journal-title":"Amyloid"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/13506129.2015.1051219","article-title":"Prevalence of the amyloidogenic transthyretin (ttr) v122i allele in 14 333 african-americans","volume":"22","author":"Jacobson","year":"2015","journal-title":"Amyloid"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000490553","article-title":"Epidemiology of transthyretin familial amyloid polyneuropathy in portugal: A nationwide study","volume":"51","author":"Ines","year":"2018","journal-title":"Neuroepidemiology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13023-025-03547-0","article-title":"Epidemiology of transthyretin (attr) amyloidosis: A systematic literature review","volume":"20","author":"Delgado","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e003781","DOI":"10.1136\/openhrt-2025-003781","article-title":"Prevalence and incidence of amyloid transthyretin amyloidosis in the USA: Insights from claims databases and electronic health records","volume":"12","author":"Laires","year":"2025","journal-title":"Open Heart"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jjcc.2022.01.002","article-title":"Incidence, clinical characteristics, and diagnostic approach in transthyretin amyloid cardiomyopathy: The kumamoto cardiac amyloidosis survey","volume":"80","author":"Takashio","year":"2022","journal-title":"J. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40119-019-0142-5","article-title":"Estimating the prevalence of transthyretin amyloid cardiomyopathy in a large in-hospital database in Japan","volume":"8","author":"Winburn","year":"2019","journal-title":"Cardiol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/mus.26034","article-title":"Estimating the global prevalence of transthyretin familial amyloid polyneuropathy","volume":"57","author":"Schmidt","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ejhf.2776","article-title":"Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy","volume":"25","author":"Porcari","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jhsa.2019.06.016","article-title":"Carpal tunnel syndrome: A potential early, red-flag sign of amyloidosis","volume":"44","author":"Donnelly","year":"2019","journal-title":"J. Hand Surg. Am."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1212\/CPJ.0000000000000640","article-title":"Carpal tunnel syndrome and associated symptoms as first manifestation of hattr amyloidosis","volume":"9","author":"Karam","year":"2019","journal-title":"Neurol. Clin. Pract."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jhsa.2022.02.013","article-title":"Prevalence and subtypes of tenosynovial amyloid in patients undergoing carpal tunnel release","volume":"47","author":"DiBenedetto","year":"2022","journal-title":"J. Hand Surg. Am."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"102890","DOI":"10.1016\/j.jchf.2025.102890","article-title":"Early diagnosis of attr-cm using carpal tunnel biopsy examination: Educate: A united kingdom prospective multicenter study","volume":"14","author":"Razvi","year":"2026","journal-title":"JACC Heart Fail."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Aldinc, E., Campbell, C., Gustafsson, F., Beveridge, A., Macey, R., Marr, L., Summers, C., and Zhang, D. (2023). Musculoskeletal manifestations associated with transthyretin-mediated (attr) amyloidosis: A systematic review. BMC Musculoskelet. Disord., 24.","DOI":"10.1186\/s12891-023-06853-5"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s13023-023-02962-5","article-title":"A 15-year consolidated overview of data in over 6000 patients from the transthyretin amyloidosis outcomes survey (thaos)","volume":"18","author":"Gentile","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: Thaos (transthyretin amyloid outcome survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1007\/s00018-009-0109-0","article-title":"Transthyretin: The servant of many masters","volume":"66","author":"Buxbaum","year":"2009","journal-title":"Cell Mol. Life Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40120-020-00217-0","article-title":"A narrative review of the role of transthyretin in health and disease","volume":"9","author":"Liz","year":"2020","journal-title":"Neurol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1073\/pnas.90.6.2375","article-title":"Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone","volume":"90","author":"Episkopou","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"16427","DOI":"10.1073\/pnas.202495199","article-title":"Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity","volume":"99","author":"Jiang","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/cpdd.700","article-title":"First-in-human study of ag10, a novel, oral, specific, selective, and potent transthyretin stabilizer for the treatment of transthyretin amyloidosis: A phase 1 safety, tolerability, pharmacokinetic, and pharmacodynamic study in healthy adult volunteers","volume":"9","author":"Fox","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/mus.20821","article-title":"The molecular biology and clinical features of amyloid neuropathy","volume":"36","author":"Benson","year":"2007","journal-title":"Muscle Nerve"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.15252\/emmm.201505357","article-title":"A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis","volume":"7","author":"Marcoux","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Koike, H., and Katsuno, M. (2021). The ultrastructure of tissue damage by amyloid fibrils. Molecules, 26.","DOI":"10.3390\/molecules26154611"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/13506129.2024.2405948","article-title":"Amyloid nomenclature 2024: Update, novel proteins, and recommendations by the international society of amyloidosis (isa) nomenclature committee","volume":"31","author":"Buxbaum","year":"2024","journal-title":"Amyloid"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000006543","article-title":"Natural history and survival in stage 1 val30met transthyretin familial amyloid polyneuropathy","volume":"91","author":"Coelho","year":"2018","journal-title":"Neurology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13023-017-0726-x","article-title":"Diagnosis and management of transthyretin familial amyloid polyneuropathy in japan: Red-flag symptom clusters and treatment algorithm","volume":"13","author":"Sekijima","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1136\/jmg.40.11.e120","article-title":"Genetic study of transthyretin amyloid neuropathies: Carrier risks among french and portuguese families","volume":"40","author":"Carayol","year":"2003","journal-title":"J. Med. Genet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/13506120802193720","article-title":"Heterogeneity of penetrance in familial amyloid polyneuropathy, attr val30met, in the swedish population","volume":"15","author":"Hellman","year":"2008","journal-title":"Amyloid"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/ana.27203","article-title":"A multicenter study of hereditary transthyretin amyloidosis in China","volume":"97","author":"Chu","year":"2025","journal-title":"Ann. Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/jnnp-2013-305383","article-title":"Overcoming artefact: Anticipation in 284 portuguese kindreds with familial amyloid polyneuropathy (fap) attrv30m","volume":"85","author":"Lemos","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e028973","DOI":"10.1161\/JAHA.122.028973","article-title":"Clinical penetrance of the transthyretin v122i variant in older black patients with heart failure: The scan-mp (screening for cardiac amyloidosis with nuclear imaging in minority populations) study","volume":"12","author":"Madhani","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"11645","DOI":"10.1038\/s41598-021-91113-6","article-title":"Association of the transthyretin variant v122i with polyneuropathy among individuals of african ancestry","volume":"11","author":"Parker","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/13506129.2023.2178891","article-title":"A multicentric study of the disease risks and first manifestations in hereditary transthyretin amyloidosis (attrv): Insights for an earlier diagnosis","volume":"30","author":"Gorram","year":"2023","journal-title":"Amyloid"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/13506129.2012.712925","article-title":"Familial amyloidosis with polyneuropathy associated with ttr ser50arg mutation","volume":"19","author":"Soto","year":"2012","journal-title":"Amyloid"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1212\/WNL.0000000000012965","article-title":"Cns involvement in hereditary transthyretin amyloidosis","volume":"97","author":"Sousa","year":"2021","journal-title":"Neurology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"20508","DOI":"10.1038\/s41598-024-71446-8","article-title":"Assessment of transthyretin instability in patients with wild-type transthyretin amyloid cardiomyopathy","volume":"14","author":"Iino","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: A population-based autopsy study","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Ann. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction","volume":"6","author":"AbouEzzeddine","year":"2021","journal-title":"JAMA Cardiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e70056","DOI":"10.1111\/jns.70056","article-title":"A novel case of nerve biopsy proven wild type transthyretin (ttr) amyloidosis","volume":"30","author":"Daley","year":"2025","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/mus.10452","article-title":"Contribution of wild-type transthyretin to hereditary peripheral nerve amyloid","volume":"28","author":"Yazaki","year":"2003","journal-title":"Muscle Nerve"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1006\/bbrc.2000.3203","article-title":"Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin","volume":"274","author":"Yazakia","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40119-020-00205-3","article-title":"Estimating the gender distribution of patients with wild-type transthyretin amyloid cardiomyopathy: A systematic review and meta-analysis","volume":"10","author":"Kroi","year":"2021","journal-title":"Cardiol. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.23521","article-title":"Liver transplantation and transthyretin amyloidosis","volume":"47","author":"Benson","year":"2013","journal-title":"Muscle Nerve"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2025.2611257","article-title":"Long-term outcome of acquired transthyretin amyloidosis","volume":"6","author":"Misumi","year":"2026","journal-title":"Amyloid"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4254\/wjh.v9.i3.126","article-title":"Iatrogenic amyloid polyneuropathy after domino liver transplantation","volume":"9","author":"Mnatsakanova","year":"2017","journal-title":"World J. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jns.12153","article-title":"\u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy","volume":"21","author":"Conceicao","year":"2016","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/13506129.2003.12088568","article-title":"Transthyretin-derived senile systemic amyloidosis: Clinicopathologic and structural considerations","volume":"10","author":"Westermark","year":"2003","journal-title":"Amyloid"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jchf.2021.05.005","article-title":"Sex-related risk of cardiac involvement in hereditary transthyretin amyloidosis: Insights from thaos","volume":"9","author":"Caponetti","year":"2021","journal-title":"JACC Heart Fail."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: A review","volume":"331","author":"Ruberg","year":"2024","journal-title":"JAMA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaccao.2021.07.010","article-title":"Electrophysiological manifestations of cardiac amyloidosis: Jacc: Cardiooncology state-of-the-art review","volume":"3","author":"Hartnett","year":"2021","journal-title":"JACC CardioOncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1001\/jamacardio.2025.2948","article-title":"Transthyretin cardiac amyloidosis in older black and hispanic individuals with heart failure","volume":"10","author":"Ruberg","year":"2025","journal-title":"JAMA Cardiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/archneur.59.11.1771","article-title":"Type i (transthyretin met30) familial amyloid polyneuropathy in Japan: Early- vs. late-onset form","volume":"59","author":"Koike","year":"2002","journal-title":"Arch. Neurol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2019.17935","article-title":"Association of the v122i hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of african or hispanic\/latino ancestry","volume":"322","author":"Damrauer","year":"2019","journal-title":"JAMA"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/jamacardio.2024.5221","article-title":"Clinical phenotype and prognosis of asymptomatic patients with transthyretin cardiac amyloid infiltration","volume":"10","author":"Porcari","year":"2025","journal-title":"JAMA Cardiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1474-4422(23)00334-4","article-title":"Hereditary transthyretin amyloid neuropathies: Advances in pathophysiology, biomarkers, and treatment","volume":"22","author":"Adams","year":"2023","journal-title":"Lancet Neurol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/ana.26965","article-title":"Amyloid neuropathy: From pathophysiology to treatment in light-chain amyloidosis and hereditary transthyretin amyloidosis","volume":"96","author":"Chompoopong","year":"2024","journal-title":"Ann. Neurol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mus.28026","article-title":"Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the united states: Recommendations from a panel of experts","volume":"69","author":"Karam","year":"2024","journal-title":"Muscle Nerve"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Zivkovic, S.A., Lacomis, D., and Soman, P. (2024). Neuromuscular manifestations of wild type transthyretin amyloidosis: A review and single center\u2019s experience. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1345608"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1212\/01.WNL.0000132966.36437.12","article-title":"Pathology of early- vs. late-onset ttr met30 familial amyloid polyneuropathy","volume":"63","author":"Koike","year":"2004","journal-title":"Neurology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1212\/WNL.0000000000001870","article-title":"Rapid progression of familial amyloidotic polyneuropathy: A multinational natural history study","volume":"85","author":"Adams","year":"2015","journal-title":"Neurology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"497-e36","DOI":"10.1111\/ene.13845","article-title":"Upper limb onset of hereditary transthyretin amyloidosis is common in non-endemic areas","volume":"26","author":"Theaudin","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"ref_76","first-page":"1","article-title":"Characteristics and natural history of autonomic involvement in hereditary attr amyloidosis: A systematic review","volume":"29","year":"2019","journal-title":"Clin. Auton. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10286-019-00628-6","article-title":"Diagnosis and treatment of gastrointestinal dysfunction in hereditary ttr amyloidosis","volume":"29","author":"Obici","year":"2019","journal-title":"Clin. Auton. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1212\/WNL.0000000000005777","article-title":"Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy","volume":"91","author":"Lozeron","year":"2018","journal-title":"Neurology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/13506129.2024.2435573","article-title":"Pathogenesis, manifestations, diagnosis, and management of cns complications in hereditary attr amyloidosis","volume":"32","author":"Sekijima","year":"2025","journal-title":"Amyloid"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1212\/01.WNL.0000065901.18353.AB","article-title":"Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant tyr69his","volume":"60","author":"Blevins","year":"2003","journal-title":"Neurology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1212\/WNL.0000000000003001","article-title":"Cerebral amyloid angiopathy in posttransplant patients with hereditary attr amyloidosis","volume":"87","author":"Sekijima","year":"2016","journal-title":"Neurology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1080\/13506129.2025.2579652","article-title":"Clinical and radiological stabilization following vutrisiran treatment in transthyretin leptomeningeal amyloidosis: A case report","volume":"33","author":"Rossi","year":"2026","journal-title":"Amyloid"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3109\/13506129.2015.1015678","article-title":"Ophthalmological manifestations in hereditary transthyretin (attr v30m) carriers: A review of 513 cases","volume":"22","author":"Beirao","year":"2015","journal-title":"Amyloid"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ajo.2017.09.001","article-title":"Ocular manifestations of familial transthyretin amyloidosis","volume":"183","author":"Reynolds","year":"2017","journal-title":"Am. J. Ophthalmol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Minnella, A.M., Rissotto, R., Antoniazzi, E., Di Girolamo, M., Luigetti, M., Maceroni, M., Bacherini, D., Falsini, B., Rizzo, S., and Obici, L. (2021). Ocular involvement in hereditary amyloidosis. Genes, 12.","DOI":"10.3390\/genes12070955"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/ajcp\/52.6.714","article-title":"Hereditary amyloidosis, the flexor retinaculum, and the carpal tunnel syndrome","volume":"52","author":"Lambird","year":"1969","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3109\/13506129.2015.1115758","article-title":"Knee osteoarthritis associated with different kinds of amyloid deposits and the impact of aging on type of amyloid","volume":"23","author":"Yanagisawa","year":"2016","journal-title":"Amyloid"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/modpathol.2014.102","article-title":"Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis","volume":"28","author":"Yanagisawa","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2017.9236","article-title":"Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis","volume":"318","author":"Geller","year":"2017","journal-title":"JAMA"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jamacardio.2024.4578","article-title":"Kidney outcomes in transthyretin amyloid cardiomyopathy","volume":"10","author":"Ioannou","year":"2025","journal-title":"JAMA Cardiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/ckj\/sfac118","article-title":"Kidney involvement in hereditary transthyretin amyloidosis: A cohort study of 103 patients","volume":"15","author":"Solignac","year":"2022","journal-title":"Clin. Kidney J."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"106761","DOI":"10.1016\/j.rmed.2022.106761","article-title":"Clinical, radiologic, and pathologic features and outcomes of pulmonary transthyretin amyloidosis","volume":"194","author":"Eggleston","year":"2022","journal-title":"Respir. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1080\/13506129.2022.2031963","article-title":"Bone marrow amyloid: A comprehensive analysis of 1469 samples, including amyloid type, clinical features, and morphologic distribution","volume":"29","author":"Chiu","year":"2022","journal-title":"Amyloid"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an rnai therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: A randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jamaneurol.2024.4631","article-title":"Five-year results with patisiran for hereditary transthyretin amyloidosis with polyneuropathy: A randomized clinical trial with open-label extension","volume":"82","author":"Adams","year":"2025","journal-title":"JAMA Neurol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by ag10 in symptomatic transthyretin amyloid cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_102","unstructured":"Glenner, G., Costa, P., and de Freitas, A. (1980). Forty years of experience with type i amyloid neuropathy: Review of 483 cases. Amyloid and Amyloidosis, Excerpta."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/ejhf.2589","article-title":"Prevalence and clinical outcomes of transthyretin amyloidosis: A systematic review and meta-analysis","volume":"24","author":"Antonopoulos","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/13506129.2021.2013193","article-title":"Describing mode of death in three major cardiac amyloidosis subtypes to improve management and survival","volume":"29","author":"Kharoubi","year":"2022","journal-title":"Amyloid"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/13506129.2011.574354063","article-title":"A homozygote case of familial amyloid polyneuropathy amyloidgenic transthyretin val30met in a non-endemic area","volume":"18","author":"Kumabe","year":"2011","journal-title":"Amyloid"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/mus.21028","article-title":"Amyloidogenic transthyretin val30met homozygote showing unusually early-onset familial amyloid polyneuropathy","volume":"37","author":"Tojo","year":"2008","journal-title":"Muscle Nerve"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1136\/jnnp-2023-332180","article-title":"Detailed clinical, physiological and pathological phenotyping can impact access to disease-modifying treatments in attr carriers","volume":"95","author":"Beauvais","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1080\/14796678.2025.2591554","article-title":"Navigating the emerging landscape of asymptomatic attr-cm: Challenges, opportunities and the path ahead","volume":"21","author":"Porcari","year":"2025","journal-title":"Future Cardiol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/eurheartj\/ehaf667","article-title":"Transthyretin amyloid cardiomyopathy: From cause to novel treatments","volume":"47","author":"Fontana","year":"2026","journal-title":"Eur. Heart J."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","article-title":"Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis","volume":"132","author":"Fontana","year":"2015","journal-title":"Circulation"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/13506129.2021.1994386","article-title":"Tissue biopsy for the diagnosis of amyloidosis: Experience from some centres","volume":"29","author":"Benson","year":"2022","journal-title":"Amyloid"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.mayocp.2020.12.002","article-title":"The clinical impact of proteomics in amyloid typing","volume":"96","author":"Hill","year":"2021","journal-title":"Mayo Clin. Proc."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jcmg.2024.10.011","article-title":"The last decade in cardiac amyloidosis: Advances in understanding pathophysiology, diagnosis and quantification, prognosis, treatment strategies, and monitoring response","volume":"18","author":"Fontana","year":"2025","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Uneus, E.I., Wilhelmsson, C., B\u00e4ckstr\u00f6m, D., Anan, I., Wixner, J., Pilebro, B., Riklund, K., \u00d6gren, M., \u00d6green, M., and Axelsson, J. (2022). Cerebellar and cerebral amyloid visualized by [(18)f]flutemetamol pet in long-term hereditary v30m (p.V50m) transthyretin amyloidosis survivors. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.816636"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/13506129.2020.1760237","article-title":"Quantification of cardiac amyloid with [(18)f]flutemetamol in patients with v30m hereditary transthyretin amyloidosis","volume":"27","author":"Mockelind","year":"2020","journal-title":"Amyloid"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.2967\/jnumed.118.221770","article-title":"Early detection of multiorgan light-chain amyloidosis by whole-body (18)f-florbetapir pet\/ct","volume":"60","author":"Ehman","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Hancock, T.J., Williams, A.D., Foster, J.S., Wall, J.S., and Martin, E.B. (2025). Pan-amyloid reactive peptides p5+14 and p5r exhibit specific charge-dependent binding to glycosaminoglycans. Pharmaceuticals, 18.","DOI":"10.3390\/ph18091340"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jcmg.2025.01.018","article-title":"Early detection of transthyretin cardiac amyloidosis using (124)i-evuzamitide positron emission tomography\/computed tomography","volume":"18","author":"Smiley","year":"2025","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"102451","DOI":"10.1016\/j.nuclcard.2025.102451","article-title":"A tale of two tracers\u2014Amyloid imaging with investigational radiotracers iodine ((124)i) evuzamitide and (99m)tc-p5+14 (at-05)","volume":"56","author":"Martin","year":"2026","journal-title":"J. Nucl. Cardiol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1093\/eurheartj\/ehaf412","article-title":"Transthyretin amyloid cardiomyopathy: Natural history and treatment response assessed by cardiovascular magnetic resonance","volume":"46","author":"Patel","year":"2025","journal-title":"Eur. Heart J."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1212\/WNL.0000000000004178","article-title":"Sural nerve injury in familial amyloid polyneuropathy: Mr neurography vs. clinicopathologic tools","volume":"89","author":"Kollmer","year":"2017","journal-title":"Neurology"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/13506129.2022.2052838","article-title":"Guidelines and new directions in the therapy and monitoring of attrv amyloidosis","volume":"29","author":"Ando","year":"2022","journal-title":"Amyloid"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11940-024-00780-z","article-title":"Update on amyloid polyneuropathy and treatment","volume":"26","author":"Zivkovic","year":"2024","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/13506129.2018.1479249","article-title":"Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary attrv30m (p.Ttrv50m) amyloidosis patients","volume":"25","author":"Monteiro","year":"2018","journal-title":"Amyloid"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver transplantation for hereditary transthyretin amyloidosis: After 20 years still the best therapeutic alternative?","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e70526","DOI":"10.1111\/ctr.70526","article-title":"Retransplantation after acquired transthyretin amyloidosis following domino liver transplantation: Outcomes and challenges","volume":"40","author":"Duarte","year":"2026","journal-title":"Clin. Transplant."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e70070","DOI":"10.1111\/ctr.70070","article-title":"Amyloidosis and heart transplantation in a new era","volume":"39","author":"Lyle","year":"2025","journal-title":"Clin. Transplant."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.mayocp.2025.05.009","article-title":"Heart transplantation for cardiac amyloidosis: Mayo clinic consensus statement","volume":"100","author":"Lyle","year":"2025","journal-title":"Mayo Clin. Proc."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"14228","DOI":"10.1021\/acs.jmedchem.0c00934","article-title":"Transthyretin amyloidogenesis inhibitors: From discovery to current developments","volume":"63","author":"Yokoyama","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"15051","DOI":"10.1073\/pnas.93.26.15051","article-title":"Inhibiting transthyretin amyloid fibril formation via protein stabilization","volume":"93","author":"Miroy","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: A randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1002\/acn3.52158","article-title":"Diflunisal versus tafamidis on neuropathy and cardiomyopathy in hereditary transthyretin amyloidosis","volume":"11","author":"Chao","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","article-title":"Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy","volume":"260","author":"Coelho","year":"2013","journal-title":"J. Neurol."},{"key":"ref_136","first-page":"s00441793936","article-title":"Real-world tafamidis experience in hereditary transthyretin amyloidosis with peripheral neuropathy in Brazil","volume":"83","author":"Pinto","year":"2025","journal-title":"Arq. Neuropsiquiatr."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e70088","DOI":"10.1111\/jns.70088","article-title":"Impact of high-dose tafamidis on hereditary attr (attrv) amyloidosis with central nervous system involvement: Two case reports with clinical, radiological and cerebrospinal fluid follow up","volume":"30","author":"Zhang","year":"2025","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jamacardio.2025.4477","article-title":"Efficacy of acoramidis in wild-type and variant transthyretin amyloid cardiomyopathy: Results from attribute-cm and its open-label extension","volume":"11","author":"Alexander","year":"2026","journal-title":"JAMA Cardiol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"101948","DOI":"10.1016\/j.nuclcard.2024.101948","article-title":"Rationale & design of act-early, the acoramidis transthyretin amyloidosis prevention trial: Early detection using cardiac radionuclide imaging","volume":"38","author":"Soman","year":"2024","journal-title":"J. Nucl. Cardiol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40259-023-00577-7","article-title":"RNA targeting and gene editing strategies for transthyretin amyloidosis","volume":"37","author":"Ioannou","year":"2023","journal-title":"BioDrugs"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/jns.12519","article-title":"Liver-directed drugs for transthyretin-mediated amyloidosis","volume":"27","author":"Brannagan","year":"2022","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13023-020-01399-4","article-title":"A phase ii, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hattr) amyloidosis","volume":"15","author":"Coelho","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.cell.2024.01.042","article-title":"Past, present, and future of crispr genome editing technologies","volume":"187","author":"Pacesa","year":"2024","journal-title":"Cell"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa2412309","article-title":"Crispr-cas9 gene editing with nexiguran ziclumeran for attr cardiomyopathy","volume":"391","author":"Fontana","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1056\/NEJMoa2510209","article-title":"Nexiguran ziclumeran gene editing in hereditary attr with polyneuropathy","volume":"393","author":"Gillmore","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1056\/NEJMc2304584","article-title":"Antibody-associated reversal of attr amyloidosis-related cardiomyopathy","volume":"388","author":"Fontana","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody ni006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Siepen","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/13506129.2024.2420809","article-title":"Prx004 in variant amyloid transthyretin (attrv) amyloidosis: Results of a phase 1, open-label, dose-escalation study","volume":"32","author":"Suhr","year":"2025","journal-title":"Amyloid"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Settelmeier, S., Agranovski, D., Steinhardt, M., Waydhas, S., Gering, I., Cejka, V., Morbach, C., St\u00f6rk, S., Willbold, D., and Kuppers, R. (2026). Transthyretin stabilizer therapy increases naturally-occurring antibodies in attr cardiomyopathy. Amyloid, 1\u201317.","DOI":"10.1080\/13506129.2026.2651299"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.1212\/WNL.0000000000011090","article-title":"Neurofilament light chain as a biomarker of hereditary transthyretin-mediated amyloidosis","volume":"96","author":"Ticau","year":"2021","journal-title":"Neurology"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.cardfail.2026.02.045","article-title":"Acoramidis, serum transthyretin, and cardiovascular outcomes in transthyretin amyloid cardiomyopathy: Insights from the attribute-cm trial","volume":"32","author":"Ambardekar","year":"2026","journal-title":"J. Card. Fail."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s43556-026-00456-x","article-title":"DNA and RNA editing for the therapy of human diseases: Current status, challenges, and future prospects","volume":"7","author":"Zhao","year":"2026","journal-title":"Mol. Biomed."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa2309915","article-title":"Gene editing for cep290-associated retinal degeneration","volume":"390","author":"Pierce","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_155","unstructured":"Wasfy, J.H., Winn, A.N., Touchette, D.R., Nikitin, D., Shah, K.K., Richardson, M., Lee, W., Kim, S., and Rind, D.M. (2024). Disease Modifying Therapies for the Treatment of Transthyretin Amyloid Cardiomyopathy, Institute for Clinical and Economic Review. Final Evidence Report."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/6\/680\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T06:06:25Z","timestamp":1781157985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/6\/680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":155,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["genes17060680"],"URL":"https:\/\/doi.org\/10.3390\/genes17060680","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]}}}